2016 年第 4 期 第 14 卷

替吉奥单药三线或多线治疗老年晚期非小细胞肺癌的临床观察

作者：

单位：

关键词：替吉奥晚期非小细胞肺癌三线或多线治疗

• 摘要：
• 【摘要】目的 观察替吉奥单药三线或多线治疗老年晚期非小细胞肺癌的有效性及安全性。方法 回顾性分析我院门诊收治的40例老年晚期非小细胞肺癌患者，服用替吉奥单药80mg/（m2˙d）分早晚两次服用，连用21天，休息7天，28天为1周期，每2周期评估近期疗效及毒性不良反应。结果 可评价疗效病例40例，疗效评价中获得完全缓解、部分缓解、病情稳定及病情进展的患者数分别为0例、3例（占7.5%）、22例（占55%）、15例（占37.5%），客观缓解率为7.5%（3/40），疾病控制率为62.5%（25/40），中位无进展生存期为3.6个月[95%CI（2.1，4.9）]。治疗后30%的患者体力状态有所改善。最常见的不良反应为恶心呕吐29例（72.5%）、厌食28例（70%），乏力28例（70%）、白细胞减少18例（45%）、血小板减少11例（27.5%）、贫血9例（22.5%），且仅有2例为Ⅲ度白细胞减少，其他均为Ⅰ~Ⅱ度骨髓抑制，全组患者未观察到Ⅳ度骨髓抑制；未观察到药物相关严重不良反应或死亡。结论 替吉奥单药治疗老年晚期非小细胞肺癌疗效较好，且毒副作用较轻，部分患者生活质量可以得到改善，可作为晚期非小细胞肺癌三线或多线的治疗方案。
• Objective To evaluate the efficacy and adverse effects of S-1 as the third-line or further-line treatment in elderly patients with advanced non-small-cell lung cancer(NLCLC). Methods Retrospective analysis of 40 elderly patients with advanced NSCLC received of S-1 capsules orally 80mg/（m2˙d）on days 1-21, rest 7 days for a cycles, efficacy and toxicities were evaluated at end of every 2 cycles. Results All of the patients were evaluable. In the therapeutic evaluation, the numbers of patients who had complete remission, partial remission, stabilization of the disease and progress of the disease were 0, 3, 22 and 15, with an objective effective rate of 7.5(3/40), a disease control rate of 62.5%(25/40) and a median progression-free survival of 3.6 months[95%CI（2.1，4.9）].30% of patients had performance status improved after treatment. The numbers of patients who had nausea and vomiting, anorexia, fatigue, leukopenia, thrombocytopenia and anemia were 29(72.5%), 28(70%), 28(70%), 18(45%), 11(27.5%) and 9(22.5%). And there were only 2 cases of Ⅲ°leukopenia, the others each symptom were at Ⅰ~Ⅱ°level, and no death induced by chemotherapy occurred. Conclusion The efficacy of S-1 as the third-line or further-line chemotherapy is good in the treatment of advanced NSCLC and few toxic and side effects, the quality of life of some patients can be improved.